Pharmaceutical Technology on MSN

FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...
Medical Marketing & Media

Rx Rundown: Recordati, Eli Lilly, AstraZeneca and more

Private equity firm CVC Capital Partners and Groupe Bruxelles Lambert launched a $12.4 billion takeover bid for Recordati. Eli Lilly announced plans to acquire three early and mid-stage vaccine ...
Fierce Biotech

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
Fierce Pharma

AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC

AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab ...

AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation

AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu in early-stage HER2-positive breast cancer in both ...

FDA delays decision on AstraZeneca breast cancer pill

The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive ...

AstraZeneca falls 7% as Q4 net profit declines 23%; here's a trading strategy for the pharma stock

An analyst said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader ...

AstraZeneca says FDA has delayed review of breast cancer therapy camizestrant

AstraZeneca (AZN) stock is in focus as the FDA delays review of a breast cancer therapy containing its next-gen oral SERD ...

AstraZeneca stock falls after FDA panel votes against new cancer drug

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

AstraZeneca's blood pressure drug wins U.S. approval

By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill baxdrostat had been approved in the United States, offering a new treatment option ...